Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
Completed
This phase II trial studies the side effects of giving intensity-modulated radiation therapy together with cisplatin and bevacizumab followed by carboplatin and cisplatin and to see how well they work in treating patients who have undergone surgery for high-risk endometrial cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, carboplatin,... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/15/2018
Locations: Paoli Memorial Hospital, Paoli, Pennsylvania +2 locations
Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/11/2017
Locations: Chestnut Hill Healthcare Cancer Center, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Terminated
This phase I/II trial studies the side effects and best dose of romidepsin when given together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well they work in treating patients with metastatic inflammatory breast cancer. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2017
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them with specialized radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the effectiveness of radiation therapy combined with paclitaxel and carboplatin in treating patients who have stage III non... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2017
Locations: Albert Einstein Cancer Center, Philadelphia, Pennsylvania
Conditions: Lung Cancer
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Terminated
Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/08/2017
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Undifferentiated Ovarian Carcinoma
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Terminated
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2017
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Pancreatic Cancer
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed
Phase II trial to study the effectiveness of CT-2103 in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/12/2017
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Terminated
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2017
Locations: Not set, Philadelphia, Pennsylvania +1 locations
Conditions: HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Completed
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to lower the risk that the cancer will come back (adjuvant therapy). Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/12/2017
Locations: Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania +12 locations
Conditions: Breast Cancer
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Terminated
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/22/2017
Locations: Research Site, Abington, Pennsylvania +7 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
Completed
This is a dose-finding study; therefore, there is no hypothesis testing
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/22/2017
Locations: Pfizer Investigational Site, Philadelphia, Pennsylvania
Conditions: Neoplasms
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Completed
The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2017
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Urologic Neoplasm